BorsaDEX+
Kripto AlPiyasalarSpotVadeli İşlemler500XBirikimEtkinlikler
Daha Fazla
ELIZAOS Etkinliği
SHANGHAI, CAMBRIDGE, Mass. and ROTTERDAM, Netherlands, Dec. 16, 2025 /PRNewswire/ — Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed toSHANGHAI, CAMBRIDGE, Mass. and ROTTERDAM, Netherlands, Dec. 16, 2025 /PRNewswire/ — Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to

Harbour BioMed Enters into Global Strategic Collaboration and License Agreement with Bristol Myers Squibb to Discover and Develop Next-Generation Multi-Specific Antibodies

Yazar: AI JournalKaynak: AI Journal
2025/12/17 09:15
Multichain
MULTI$0.03871-3.65%
MASS
MASS$0.000396-9.38%

SHANGHAI, CAMBRIDGE, Mass. and ROTTERDAM, Netherlands, Dec. 16, 2025 /PRNewswire/ — Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology and oncology, today announced a multi-year, global strategic collaboration and license agreement with Bristol Myers Squibb to discover and develop next-generation multi-specific antibodies.

Under the terms of the agreement, Harbour BioMed will collaborate with Bristol Myers Squibb to advance and accelerate multi-specific antibody discovery programs. In return, Harbour BioMed could receive payments totaling $90 million, as well as development and commercial milestones of up to $1.035 billion, along with tiered royalties should Bristol Myers Squibb elect to advance all potential programs.

Jingsong Wang, MD, PhD, Founder, Chairman, and CEO of Harbour BioMed, commented: “We are delighted to collaborate with Bristol Myers Squibb to advance next-generation multi-specific antibody discovery and development. This collaboration leverages our Harbour Mice® fully human antibody technology platform, which facilitates the efficient discovery and development of innovative biologics with enhanced therapeutic potential. Furthermore, the collaboration offers the possibility to utilize our established development capabilities to accelerate programs by conducting early clinical trials in China. By uniting the strengths of our platform with Bristol Myers Squibb’s expertise in drug discovery and development, we look forward to progressing these programs and delivering transformative therapies to patients worldwide.”

About Harbour BioMed

Harbour BioMed (HKEX: 02142) is a global biopharmaceutical company committed to the discovery, development, and commercialization of novel antibody therapeutics focusing on immunology and oncology. The company is building its robust portfolio and differentiated pipeline through internal R&D capability, collaborations with co-discovery and co-development partners, and select acquisitions.

The proprietary antibody technology platform Harbour Mice® generates fully human monoclonal antibodies in two heavy and two light chains (H2L2) format, as well as heavy chain only (HCAb) format. Building upon the HCAb antibodies, the HCAb-based immune cell engagers (HBICE®) bispecific antibody technology is capable of delivering tumor-killing effects unachievable by traditional combination therapies. Integrating Harbour Mice®, and HBICE® with a single B cell cloning platform, our antibody discovery engine is highly unique and efficient for the development of next-generation therapeutic antibodies. For further information, please refer to www.harbourbiomed.com.

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/harbour-biomed-enters-into-global-strategic-collaboration-and-license-agreement-with-bristol-myers-squibb-to-discover-and-develop-next-generation-multi-specific-antibodies-302644075.html

SOURCE Harbour BioMed

Piyasa Fırsatı
Multichain Logosu
Multichain Fiyatı(MULTI)
$0.03871
$0.03871$0.03871
+0.62%
USD
Multichain (MULTI) Canlı Fiyat Grafiği
Sorumluluk Reddi: Bu sitede yeniden yayınlanan makaleler, halka açık platformlardan alınmıştır ve yalnızca bilgilendirme amaçlıdır. MEXC'nin görüşlerini yansıtmayabilir. Tüm hakları telif sahiplerine aittir. Herhangi bir içeriğin üçüncü taraf haklarını ihlal ettiğini düşünüyorsanız, kaldırılması için lütfen service@support.mexc.com ile iletişime geçin. MEXC, içeriğin doğruluğu, eksiksizliği veya güncelliği konusunda hiçbir garanti vermez ve sağlanan bilgilere dayalı olarak alınan herhangi bir eylemden sorumlu değildir. İçerik, finansal, yasal veya diğer profesyonel tavsiye niteliğinde değildir ve MEXC tarafından bir tavsiye veya onay olarak değerlendirilmemelidir.

Ayrıca Şunları da Beğenebilirsiniz

Crypto ETF Floodgates Open With SEC Listing Standards. What Does It Mean For Prices?

Crypto ETF Floodgates Open With SEC Listing Standards. What Does It Mean For Prices?

The post Crypto ETF Floodgates Open With SEC Listing Standards. What Does It Mean For Prices? appeared on BitcoinEthereumNews.com. The U.S. Securities and Exchange Commission (SEC) has cleared a path for a flood of new crypto exchange-traded products to hit the market, a move analysts say could reshape how money flows into digital assets. On Wednesday, the agency approved generic listing standards for “commodity-based trust shares” across regulated exchanges Nasdaq, Cboe BZX and NYSE Arca. Read more: SEC Makes Spot Crypto ETF Listing Process Easier, Approves Grayscale’s Large-Cap Crypto Fund The new rules remove the need for each crypto ETP to undergo its own individual rule filing under Section 19(b) of the Exchange Act. Instead, an offering whose underlying assets satisfy certain objective eligibility tests — for example, if the crypto trades on a market that is a member of the Intermarket Surveillance Group (ISG), or if the underlying asset’s futures contract is listed on a CFTC-regulated designated contract market for at least six months — can be listed using these generic standards. What’s next? The regulatory shift marks a watershed for the crypto industry, removing much of the procedural drag that has historically slowed getting new crypto products to the market, analysts said. “[The] crypto ETF floodgates are about to open,” said Nate Geraci, a well-followed ETF analyst and president of NovaDius Wealth Management. “Expect an absolute deluge of new filings and launches,” he said. “You may not like it, but crypto is going mainstream via the ETF wrapper.” Matt Hougan, chief investment officer of digital asset management firm and ETF issuer Bitwise, said the SEC’s move is a “coming of age” moment for crypto. “[It’s] a signal that we’ve reached the big leagues,” he wrote. “But it’s also just the beginning.” History backs up predictions that the number of new crypto ETF launches will accelerate under the new regime. When the SEC approved generic listing standards for…
Paylaş
BitcoinEthereumNews2025/09/20 14:14
OpenVPP accused of falsely advertising cooperation with the US government; SEC commissioner clarifies no involvement

OpenVPP accused of falsely advertising cooperation with the US government; SEC commissioner clarifies no involvement

PANews reported on September 17th that on-chain sleuth ZachXBT tweeted that OpenVPP ( $OVPP ) announced this week that it was collaborating with the US government to advance energy tokenization. SEC Commissioner Hester Peirce subsequently responded, stating that the company does not collaborate with or endorse any private crypto projects. The OpenVPP team subsequently hid the response. Several crypto influencers have participated in promoting the project, and the accounts involved have been questioned as typical influencer accounts.
Paylaş
PANews2025/09/17 23:58
US Senators Introduce SAFE Crypto Act to Target Rising Crypto Scams

US Senators Introduce SAFE Crypto Act to Target Rising Crypto Scams

The post US Senators Introduce SAFE Crypto Act to Target Rising Crypto Scams appeared first on Coinpedia Fintech News Crypto scams are getting faster, smarter and
Paylaş
CoinPedia2025/12/17 18:33